• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

实践参数:帕金森病的神经保护策略及替代疗法(循证综述):美国神经病学学会质量标准小组委员会报告

Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

作者信息

Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner W J

机构信息

University of Calgary, Calgary, AB, Canada.

出版信息

Neurology. 2006 Apr 11;66(7):976-82. doi: 10.1212/01.wnl.0000206363.57955.1b.

DOI:10.1212/01.wnl.0000206363.57955.1b
PMID:16606908
Abstract

OBJECTIVE

To define key issues in the management of Parkinson disease (PD) relating to neuroprotective strategies and alternative treatments, and to make evidence-based treatment recommendations.

METHODS

Two clinical questions were identified. 1) In a patient diagnosed with PD, are there any therapies that can slow disease progression? 2) Are there any nonstandard pharmacologic or nonpharmacologic therapies that have been shown to improve motor function in PD? Articles were classified according to a four-tiered level of evidence scheme. Recommendations were based on the evidence.

RESULTS AND CONCLUSIONS

  1. Levodopa does not appear to accelerate disease progression. 2. No treatment has been shown to be neuroprotective. 3. There is no evidence that vitamin or food additives can improve motor function in PD. 4. Exercise may be helpful in improving motor function. 5. Speech therapy may be helpful in improving speech volume. 6. No manual therapy has been shown to be helpful in the treatment of motor symptoms, although studies in this area are limited. Further studies using a rigorous scientific method are needed to determine efficacy of alternative therapies.
摘要

目的

明确帕金森病(PD)管理中与神经保护策略及替代治疗相关的关键问题,并提出基于证据的治疗建议。

方法

确定了两个临床问题。1)在确诊为PD的患者中,是否有任何疗法可减缓疾病进展?2)是否有任何非标准的药物或非药物疗法已被证明可改善PD患者的运动功能?文章根据四级证据方案进行分类。建议基于证据。

结果与结论

  1. 左旋多巴似乎不会加速疾病进展。2. 尚无治疗被证明具有神经保护作用。3. 没有证据表明维生素或食品添加剂可改善PD患者的运动功能。4. 运动可能有助于改善运动功能。5. 言语治疗可能有助于提高音量。6. 尽管该领域的研究有限,但尚无手法治疗被证明对运动症状治疗有帮助。需要采用严格科学方法进行进一步研究以确定替代疗法的疗效。

相似文献

1
Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.实践参数:帕金森病的神经保护策略及替代疗法(循证综述):美国神经病学学会质量标准小组委员会报告
Neurology. 2006 Apr 11;66(7):976-82. doi: 10.1212/01.wnl.0000206363.57955.1b.
2
Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.实践参数:帕金森病的神经保护策略及替代疗法(循证综述):美国神经病学学会质量标准小组委员会报告
Neurology. 2007 Jan 9;68(2):164; author reply 164. doi: 10.1212/01.wnl.0000254819.77545.da.
3
Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review) [RETIRED]: report of the Quality Standards Subcommittee of the American Academy of Neurology.实践参数:新发帕金森病的诊断与预后(循证综述)[已退休]:美国神经病学学会质量标准小组委员会报告
Neurology. 2006 Apr 11;66(7):968-75. doi: 10.1212/01.wnl.0000215437.80053.d0.
4
Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.实践参数:帕金森病抑郁、精神病和痴呆的评估与治疗(循证综述):美国神经病学学会质量标准小组委员会报告
Neurology. 2006 Apr 11;66(7):996-1002. doi: 10.1212/01.wnl.0000215428.46057.3d.
5
Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.实践参数:帕金森病运动波动和异动症的治疗(循证综述):美国神经病学学会质量标准小组委员会报告
Neurology. 2006 Apr 11;66(7):983-95. doi: 10.1212/01.wnl.0000215250.82576.87.
6
Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.实践参数:新发帕金森病的诊断与预后(循证综述):美国神经病学学会质量标准委员会报告
Neurology. 2006 Dec 26;67(12):2266; author reply 2266. doi: 10.1212/01.wnl.0000252726.13187.63.
7
Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology.实践参数:帕金森病非运动症状的治疗:美国神经病学学会质量标准分会的报告。
Neurology. 2010 Mar 16;74(11):924-31. doi: 10.1212/WNL.0b013e3181d55f24.
8
Practice parameter: Assessing patients in a neurology practice for risk of falls (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.实践参数:评估神经病学实践中患者的跌倒风险(循证综述):美国神经病学学会质量标准小组委员会报告
Neurology. 2008 Feb 5;70(6):473-9. doi: 10.1212/01.wnl.0000299085.18976.20.
9
Re: Practice parameter: assessing patients in a neurology practice for risk of falls (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.回复:实践参数:评估神经病学实践中患者的跌倒风险(循证综述):美国神经病学学会质量标准小组委员会报告
Neurology. 2009 Jan 27;72(4):382; author reply 382-3.
10
Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.实践参数:帕金森病抑郁、精神病和痴呆的评估与治疗(循证综述):美国神经病学学会质量标准小组委员会报告
Neurology. 2007 Jan 2;68(1):80; author reply 81. doi: 10.1212/01.wnl.0000252956.34585.a6.

引用本文的文献

1
Trends in Parkinson's disease medication prescribing patterns in the UK: An interrupted time series analysis (2019-2024).英国帕金森病药物处方模式的趋势:中断时间序列分析(2019 - 2024年)
PLoS One. 2025 May 23;20(5):e0324999. doi: 10.1371/journal.pone.0324999. eCollection 2025.
2
Drug utilization study of antiparkinsonian medication in Romania during 25 years.罗马尼亚25年间抗帕金森病药物的药物利用研究。
Front Pharmacol. 2025 Feb 5;16:1534344. doi: 10.3389/fphar.2025.1534344. eCollection 2025.
3
Tango and physiotherapy interventions in Parkinson's disease: a pilot study on efficacy outcomes on motor and cognitive skills.
探戈舞和物理疗法干预帕金森病:对运动和认知技能疗效结果的初步研究。
Sci Rep. 2024 May 24;14(1):11855. doi: 10.1038/s41598-024-62786-6.
4
Olfactory status in neurodegeneration with brain iron accumulation disorders.脑铁蓄积性神经退行性变中的嗅觉状态。
Neurol Sci. 2024 Feb;45(2):647-654. doi: 10.1007/s10072-023-07037-8. Epub 2023 Aug 31.
5
Factors affecting the choice of first-line therapy in Parkinson's disease patients in Wales: A population-based study.威尔士帕金森病患者一线治疗选择的影响因素:一项基于人群的研究。
Saudi Pharm J. 2021 Feb;29(2):206-212. doi: 10.1016/j.jsps.2021.01.004. Epub 2021 Jan 28.
6
Complementary Therapies in Parkinson Disease: a Review of Acupuncture, Tai Chi, Qi Gong, Yoga, and Cannabis.帕金森病的补充疗法:针灸、太极拳、气功、瑜伽和大麻的综述。
Neurotherapeutics. 2020 Oct;17(4):1434-1455. doi: 10.1007/s13311-020-00900-y.
7
Guidelines on exercise testing and prescription for patients at different stages of Parkinson's disease.帕金森病不同阶段患者的运动试验和运动处方指南。
Aging Clin Exp Res. 2021 Feb;33(2):221-246. doi: 10.1007/s40520-020-01612-1. Epub 2020 Jun 8.
8
Patterns and Determinants of Prescribing for Parkinson's Disease: A Systematic Literature Review.帕金森病处方模式与决定因素:一项系统文献综述
Parkinsons Dis. 2019 Nov 3;2019:9237181. doi: 10.1155/2019/9237181. eCollection 2019.
9
Dyskinesia in multiple system atrophy and progressive supranuclear palsy.多系统萎缩和进行性核上性麻痹中的运动障碍。
J Neural Transm (Vienna). 2019 Jul;126(7):925-932. doi: 10.1007/s00702-019-02012-0. Epub 2019 May 13.
10
Earlier Dopaminergic Treatment in Parkinson's Disease Is Not Associated With Improved Outcomes.帕金森病早期多巴胺能治疗与改善预后无关。
Mov Disord Clin Pract. 2019 Jan 28;6(3):222-226. doi: 10.1002/mdc3.12724. eCollection 2019 Mar.